Navigation Links
Promising Phase 3 trial results show biologic therapy ustekinumab significantly improved psoriasis
Date:10/3/2007

BUENOS AIRES, Argentina, October 3, 2007 The first reported findings from an international, Phase 3 study showed that more than two-thirds of patients with moderate to severe plaque psoriasis receiving two doses of ustekinumab (CNTO 1275) achieved at least a 75 percent reduction in psoriasis at week 12, the primary endpoint of the study, as measured by the Psoriasis Area and Severity Index (PASI 75). Importantly, findings also showed that following one additional dose at week 16, a substantial proportion of patients receiving ustekinumab maintained a PASI 75 response through week 28. Data from the study, presented at the World Congress of Dermatology, involved more than 1,200 subjects and showed that within four weeks of initiating treatment with ustekinumab, patients experienced significant and clinically meaningful improvements in quality of life measures compared with patients receiving placebo. Ustekinumab is a new, fully-human monoclonal antibody with a novel mechanism of action that targets the cytokines interleukin-12 (IL-12) and interleukin-23 (IL-23), and is currently in Phase 3 development by Centocor, Inc. for the treatment of moderate to severe plaque psoriasis.

These data, presented at the 21st meeting of the World Congress of Dermatology, will be the subject of a live press briefing and webcast (www.cnto1275wcd.com) today at 2 p.m. EDT featuring Craig Leonardi, MD, St. Louis University Medical School, St. Louis, MO, Kristian Reich, MD, Georg-August-University, Gttingen, Germany, Silvia Fernandez Barrio, executive director, Civil Association of Psoriasis Patients of Argentina, Buenos Aires, Argentina, and Tom Schaible, PhD, vice president, Medical Affairs, Centocor, Inc.

These findings provide further evidence of the role of IL-12/23 in the pathogenesis of psoriasis and the promise that a new therapeutic approach like ustekinumab may hold for dermatologists and their patients living w
'/>"/>

Contact: Michael Parks
215-325-4010
Centocor, Inc.
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. PCR emerging as a promising technique for Diagnosing Urinary Tuberculosis
2. Experimental treatment for Ebola Virus Shows promising results in mice
3. Promising Treatment for Diabetes
4. A promising treatment for wart removal
5. Hepatitis shots is promising
6. Life after Bypass not so Promising for Women.
7. Promising cure for West Nile Virus
8. Deadly Diarrhoea Vaccine – Trail Results Promising
9. Novartis MS Drug Shows Promising Results
10. Sunitinib a Promising Agent for Treatment of Renal Cell Cancer
11. Research Ethics Requirements Compromising Quality of Health Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2015)... On Thursday, May 14, the ... and Dr. Evan Alley both of the University ... Experts’ series. The interview was part of the ... excellence. Drs. Simone and Alley were interviewed by ... whom they discussed the mesothelioma program at the ...
(Date:5/30/2015)... 2015 Responding to surging demand from ... experienced OGAWA products while abroad, OGAWA-engineered massage products have ... A leader in the Asian health and wellness industry ... developer and manufacturer of health and wellness equipment. ... their products, health enthusiasts in Asia and Australia, as ...
(Date:5/30/2015)... Cyclist Barry Haarde will commence his ... 2015: Piles of Miles” near San Francisco, California ... and encourage individuals to support needy hemophilic children ... Life supports nearly 1,200 impoverished children and adults ... sponsorships, scholarships and micro-enterprise grants. Hemophilia is a ...
(Date:5/30/2015)... iconic American actor, and host of “In America” James ... Medical Malpractice. This segment of “In America” will cover ... field. , According to the Bureau of Justice Statistics, ... roughly only 20% of them made it to court, ... remaining 30% were tossed out. (Source: http://www.bjs.gov/index.cfm?ty=tp&tid=4511 ) ...
(Date:5/30/2015)... (PRWEB) May 30, 2015 Venus Viva ... acne scars, large pores, deep wrinkles, stretch marks, pigmentation ... medical professional, such as Dr. F. Victor Rueckl of ... the clinical trials in Las Vegas. This body image ... into a system that delivers proven results through a ...
Breaking Medicine News(10 mins):Health News:Interview with Mesothelioma Experts, Drs. Simone and Alley Now Available on Demand 2Health News:Award-winning OGAWA Massage Chairs Finally Available for purchase in North America. 2Health News:Award-winning OGAWA Massage Chairs Finally Available for purchase in North America. 3Health News:Barry Haarde Cycles 4,000 Miles Across the USA for Hemophilia 2Health News:Announcing Ground-Breaking Technology for Anti-Aging, FDA Approved, Venus Viva. 2Health News:Announcing Ground-Breaking Technology for Anti-Aging, FDA Approved, Venus Viva. 3
... up to 24 patients ... ... Luke,s Medical Center,s,new hyperbaric chamber will triple the hospital,s capacity to ... (Photo: http://www.newscom.com/cgi-bin/prnh/20080417/AQTH107 ), The 52-foot-long, 66-ton chamber, the ...
... The American,Chemistry Council (ACC) today sent a letter ... update its review of the safety of bisphenol ... of scientific study regarding bisphenol A is well,documented ... concerns about the safety and use of polycarbonate ...
... The U.S. Agency for,International Development and Iraq,s Ministry ... (MOU) outlining a shared vision and,collaborative effort to ... health services to Iraqi citizens, and contribute to ... strengthens the strategic cooperation between the MoH and,USAID,s ...
... N.J., April 17 TeamStaff, Inc.,(Nasdaq: TSTF ), ... announced the results from the Company,s Annual,Meeting of Shareholders ... located,in Somerset, New Jersey., At the annual meeting, ... J. Delaney to serve as Class III Directors. In,addition, ...
... HVAC company provides tips for improving indoor air quality, ... National,Indoor Comfort Week, Atlas Butler Heating and Cooling is ... in their homes and offices,is free of harmful pollutants., ... indoor,environmental systems on which everyone relies, and honors the ...
... improved in patients , , THURSDAY, April 17 (HealthDay News) ... experimental Alzheimer,s drug reinforces the notion that the compound ... mild to moderate Alzheimer,s patients. , A second analysis ... also reveals that by improving the Alzheimer,s patients, ability ...
Cached Medicine News:Health News:Aurora St. Luke's Medical Center Installs the Country's Second-Largest Hyperbaric Chamber 2Health News:Aurora St. Luke's Medical Center Installs the Country's Second-Largest Hyperbaric Chamber 3Health News:Aurora St. Luke's Medical Center Installs the Country's Second-Largest Hyperbaric Chamber 4Health News:Aurora St. Luke's Medical Center Installs the Country's Second-Largest Hyperbaric Chamber 5Health News:Aurora St. Luke's Medical Center Installs the Country's Second-Largest Hyperbaric Chamber 6Health News:ACC Calls on FDA to Update Review of Bisphenol A 2Health News:ACC Calls on FDA to Update Review of Bisphenol A 3Health News:Iraq's Ministry of Health and USAID Sign Memorandum of Understanding to Increase Cooperation in Public Management 2Health News:TeamStaff, Inc. Announces Results From Annual Meeting of Shareholders 2Health News:TeamStaff, Inc. Announces Results From Annual Meeting of Shareholders 3Health News:National Indoor Comfort Week - A Breath of Fresh Air for Allergy Sufferers 2Health News:Experimental Alzheimer's Drug Shows Promise 2Health News:Experimental Alzheimer's Drug Shows Promise 3
(Date:5/29/2015)...  Today, UL LLC, a global safety science ... electronic quality management systems (EQMS) and quality consulting ... the strengths of both organizations to support the ... comprehensive advice and guidance for successful global regulatory ... UL,s strength in regulatory services and testing offers ...
(Date:5/29/2015)... Research and Markets ( http://www.researchandmarkets.com/research/64lx2w/north_america_mri ) has ... Market - Growth, Trends And Forecasts (2014 - 2019)" ... American MRI systems market is estimated to increase from ... by 2020 with a CAGR of 2.9% between 2014 ... the open system, closed system and the standing or ...
(Date:5/29/2015)... N.J. , May 29, 2015 Actinobac ... companies originally funded with investments from Foundation Venture Capital ... at Bio International 2015 as part of the Start-Up ... announced FVCG President James M. Golubieski . ... the biotechnology industry, will be held in ...
Breaking Medicine Technology:UL and MasterControl collaborate to provide medical manufacturers full service QMS and Regulatory Submissions support 2UL and MasterControl collaborate to provide medical manufacturers full service QMS and Regulatory Submissions support 3North America MRI Market - Growth, Trends And Forecasts 2014-2019 with GE, Hitachi Medical, Philips Healthcare, Siemens Healthcare & Toshiba Medical Systems Dominating 2Foundation Venture Capital Group Portfolio Companies to be Highlighted at Bio International in June 2Foundation Venture Capital Group Portfolio Companies to be Highlighted at Bio International in June 3
... Telik, Inc.,(Nasdaq: TELK ) reported positive preclinical ... molecule inhibitors of validated cancer targets,including aurora kinases ... the,AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics ... play a key role in mitosis, or cell,division. ...
... combination IV belinostat in ovarian ... cancer reported -, - Oral belinostat demonstrated to be safe and well-tolerated in Phase ... CuraGen to provide a clinical update conference call today at 5:00 p.m. ... Eastern Time -, BRANFORD, ...
Cached Medicine Technology:Telik Announces Preclinical Data Demonstrating Anti-Cancer Activity of Dual Inhibitors of Aurora Kinase and VEGFR2 2CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference 2CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference 3CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference 4CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference 5CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference 6CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference 7CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference 8CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference 9
... of guiding introducers includes Swartz™ Series, ... piece steerable, all designed for the ... varying curves and longer sheath lengths ... Jude Medical guiding introducers are designed ...
Lumenis 1000 Integrated Slit Lamp Fully-integrated biomicroscope slit lamp laser delivery system, complete with built-in LaserLink, parallel optics, magnification changer, micromanipulator and multi...
Novus 30001 A fully-integrated and powerful 532 nm Operating Room Photocoagulator with reliable DPSS technology and simplified operation using a touch screen interface and remote control....
... Selecta Trio The pinnacle ... Nd:YAG, diode-pumped solid-state (DPSS) 532 ... laser (SLT) and offering maximum ... The first and only Nd:YAG, ...
Medicine Products: